文献速递胸部肿瘤放疗放疗物理与技术

基于CT的影像组学列线图可能预测局部晚期非小细胞肺癌患者中哪些可从自适应放疗中获益

CT-based radiomics nomogram may predict who can benefit from adaptive radiotherapy in patients with local advanced-NSCLC patients.
PubMed 文献 · Radiother Oncol · 2023-03-22

研究纳入183例接受同步放化疗联合自适应放疗的局部晚期非小细胞肺癌患者作为主要队列,另28例来自另一家医院作为独立外部验证队列,基于CT提取影像组学特征并以LASSO和逻辑回归建模,结果显示Criteria A与Criteria B模型的AUC分别为0.767和0.771,模型稳定性经Bootstrap及外部验证确认。

要点

  • 基于CT的影像组学模型可筛选从自适应放疗中获益更多的局部晚期非小细胞肺癌患者。
  • Criteria A模型与Criteria B模型的AUC分别为0.767和0.771,Bootstrap及外部验证确认模型稳定。
  • 按Criterion B定义的放疗敏感患者接受自适应放疗后PFS和OS显著长于同样接受自适应放疗的抗拒患者。

核心结论

  • 基于CT的影像组学可筛选出从自适应放疗中获益更多的患者,有助于在经济性与可行性范围内指导和推广自适应放疗策略的临床应用。

研究设计与样本

  • 研究纳入183例接受同步放化疗联合自适应放疗的非小细胞肺癌患者作为主要队列,另28例来自另一家医院作为独立外部验证队列。
  • 肿瘤退缩评估依据GTV缩小(Criteria A)或依据RECIST 1.1版(Criteria B)进行。
  • 影像组学特征通过「PyRadiomics」软件包提取,并进一步以LASSO方法筛选,随后采用逻辑回归建立模型。
  • 采用Bootstrap及外部验证检验模型稳定性,并绘制受试者工作特征(ROC)曲线评估影像组学模型的预测效能。
  • 对初始计划与合成自适应放疗计划之间的剂量体积直方图进行定量比较,临床终点包括总生存(OS)和无进展生存(PFS)。

主要发现

  • 肿瘤退缩抗拒(RR)组与肿瘤退缩敏感(RS)组之间的临床特征无显著差异。
  • Criteria A模型与Criteria B模型的AUC分别为0.767和0.771。
  • Bootstrap验证和外部验证确认了模型的稳定性。
  • 在所有患者中,自适应放疗较非自适应放疗在肺、心脏、脊髓和食管方面有显著获益,尤其在RS患者中。
  • 按Criterion B定义的RS患者接受自适应放疗后的PFS和OS显著长于同样接受自适应放疗的RR患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although adaptive radiotherapy (ART) has many advantages, ART is not universal in the clinical appliance due to the consumption of a lot of labor, and economic burden. It is necessary to explore a CT stimulation-based radiomics model for screening who can get more benefits from ART in locally advanced non-small cell lung cancer (NSCLC) patients. METHOD: 183 cases of NSCLC patients receiving concurrent chemoradiotherapy with an adaptive approach were enrolled as a primary cohort, while 28 cases from another hospital served as an independent external validation cohort. Tumor regression assessment was conducted based on GTV reduction (Criteria A) or according to RECIST Version 1.1(Criteria B). The radiomics features were extracted by the "PyRadiomics" package and further screened by the LASSO method. Then, logistic regression was used to establish the model. Bootstrap and external validation were applied to verify the stability of the model. The receiver operating characteristic (ROC) curve was delineated to assess the predictive efficacy of the radiomics model. Dose-volume histograms were quantitatively compared between the initial and composite ART plans. Clinical endpoints included overall survival (OS) and progression-free survival (PFS). RESULT: There were no significant differences in clinical features between tumor regression-resistant (RR) and tumor regression-sensitivity (RS) groups. The AUC values of the Criteria A model and Criteria B model were 0.767 and 0.771, respectively. Bootstrapping validation and external validation confirmed the stability of models. In all patients, there was a significant benefit of ART in the lung, heart, cord, and esophagus compared to non-ART, particularly in RS patients. Furthermore, PFS and OS from ART were significantly longer in RS as defined by Criterion B than in RR patients with the same ART application. CONCLUSION: CT-based radiomics can screen out the patients who can gain more benefits from ART, which contribute to guiding and popularizing the application of ART strategy in the clinic within economic benefits and feasibility.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou C, Hou L, Tang X, et al. CT-based radiomics nomogram may predict who can benefit from adaptive radiotherapy in patients with local advanced-NSCLC patients. Radiother Oncol. 2023. PMID: 36963440. doi:10.1016/j.radonc.2023.109637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。